Develops injectable and inhalation drugs for diabetes and respiratory diseases.
Jun 2026Revenue $730M/yrExpenses $616M/yr
No trend
Figures by year
Is Amphastar Pharmaceuticals profitable?
Yes. In the 12 months to Jun 2026, revenue was $730M and expenses $616M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $720M | $579M | $140M |
| Dec 2024 | $732M | $527M | $205M |
| Dec 2023 | $644M | $447M | $197M |
| Dec 2022 | $499M | $391M | $107M |
| Dec 2021 | $438M | $368M | $69.9M |
| Dec 2020 | $350M | $339M | $11.0M |
| Dec 2019 | $322M | $322M | −$39.0K |
| Dec 2018 | $295M | $303M | −$8.62M |
| Dec 2017 | $240M | $241M | −$1.27M |
| Dec 2016 | $255M | $240M | $15.4M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.